Adaptive Biotechnologies Corp — Director's Dealing 2025

Mar 7, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2025-03-04

Reporting Person: GRIFFIN MICHELLE RENEE (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-03-04	Common Stock	A	15394	—	Acquired	67349	Direct
2025-03-06	Common Stock	S	15664	$7.94	Disposed	51685	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-03-04	Stock Option (right to buy)	$8.12	A	23726	Acquired	2035-03-04	Common Stock (23726)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2024.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $7.64 to $8.21, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The option will vest in equal monthly installments over one year from March 4, 2025, subject to continued service as a director through such vesting dates.